HCQ and MS; Guillain-Barre and COVID Vax; Neural Fingerprints Can Tell Who You Are

— News and commentary from the world of neurology and neuroscience

MedicalToday
Brain scan images with NeuroBreak in the center.

The antimalarial drug hydroxychloroquine (HCQ) was associated with in people with primary progressive multiple sclerosis (MS), a phase II trial showed. (Annals of Neurology)

The FDA approved injectable (Zimhi) to counter opioid overdose. The drug previously was approved in lower doses under the trade name Narcan.

Data from the Vaccine Adverse Event Reporting System (VAERS) suggested a potential small but significant safety in people who received the Johnson & Johnson COVID-19 vaccine, reinforcing the recent FDA warning. (JAMA)

Three factors -- young age, spinal cord lesions, and gadolinium-enhancing lesions on index MRI -- were linked to an in people with radiologically isolated syndrome. (JAMA Network Open)

Women have been disproportionately relative to their burden of disease. (Neurology)

Neural fingerprints -- brief segments of neurophysiological activity as short as 30 seconds -- on magnetoencephalography. (Nature Communications)

Microglia activation appeared to and 18F-fluorodeoxyglucose PET alterations in the brain. (Science Translational Medicine)

Topline phase III results showed the investigational antisense drug in amyotrophic lateral sclerosis patients with SOD1 mutations, but drugmaker Biogen said "trends favoring tofersen were seen."

Plasma glial fibrillary acidic protein (GFAP) as an indicator of amyloid-beta pathology in early Alzheimer's disease. (JAMA Neurology)

Deutetrabenazine was in a phase III trial of children and adolescents with Tourette's syndrome. (JAMA Network Open)

As it confronts greater head injury awareness, the National Football League now has , including an independent neurologist on each sideline and one in a video replay booth to scrutinize every play. (The Guardian)

Will injured kids over tackle football? (New York Times)

  • Judy George covers neurology and neuroscience news for , writing about brain aging, Alzheimer’s, dementia, MS, rare diseases, epilepsy, autism, headache, stroke, Parkinson’s, ALS, concussion, CTE, sleep, pain, and more.